Nektar Therapeutics downgraded by Goldman with a new price target
$NKTR
Biotechnology: Pharmaceutical Preparations
Health Care
Goldman downgraded Nektar Therapeutics from Neutral to Sell and set a new price target of $3.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/4/2024 | $7.00 | Overweight | Piper Sandler |
| 9/30/2024 | $4.00 | Buy | BTIG Research |
| 6/28/2024 | $2.00 | Buy | Rodman & Renshaw |
| 11/20/2023 | Underweight | JP Morgan | |
| 11/9/2023 | Market Perform → Outperform | TD Cowen | |
| 5/10/2023 | $1.50 → $1.00 | Underperform → Hold | Jefferies |
| 2/24/2023 | $3.20 → $1.50 | Hold → Underperform | Jefferies |
| 8/8/2022 | Neutral → Underweight | JP Morgan |
4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
SAN FRANCISCO, Nov. 7, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the third quarter ended September 30, 2024. Cash and investments in marketable securities on September 30, 2024 were $249.0 million as compared to $329.4 million at December 31, 2023. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth quarter of 2026. "We made excellent progress this quarter advancing our I&I pipeline, including the ongoing Phase 2b studies of rezpegaldesleukin in atopic
SAN FRANCISCO, Oct. 31, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) will announce its financial results for the third quarter 2024 on Thursday, November 7, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com/
SAN FRANCISCO, Aug. 8, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the second quarter ended June 30, 2024. Cash and investments in marketable securities at June 30, 2024 were $290.6 million as compared to $329.4 million at December 31, 2023. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the third quarter of 2026. "We continue to make excellent progress advancing rezpegaldesleukin in Phase 2 studies in patients with atopic dermatitis and alopecia areata," said
8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
10-Q - NEKTAR THERAPEUTICS (0000906709) (Filer)
– NKTR-0165 Demonstrates Selective Enhancement of Treg Cell Function Through Novel Agonistic Mechanism –– IND-Enabling Studies Underway for NKTR-0165 with First-in-Human Studies Planned in First Half of 2025 -
Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 percent. This is a 73.97 percent increase over losses of $(0.73) per share from the same period last year. The company reported quarterly sales of $21.639 million which beat the analyst consensus estimate of $15.342 million by 41.05 percent. This is a 0.21 percent increase over sales of $21.594 million the same period last year.
SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)
SC 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)
SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)
- NKTR-422 demonstrated inflammation resolution and tissue repair in multiple preclinical models of chronic inflammatory conditions - SAN FRANCISCO, Nov. 18, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced its oral presentation highlighting preclinical data on NKTR-422 at the 2024 American College of Rheumatology (ACR) conference, being held in Washington, D.C. from November 14-19, 2024. NKTR-422 is a novel modified hematopoietic colony stimulating factor (CSF) protein engineered to selectively modulate resolution processes of inflammation by targeting t
SAN FRANCISCO, Nov. 7, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the third quarter ended September 30, 2024. Cash and investments in marketable securities on September 30, 2024 were $249.0 million as compared to $329.4 million at December 31, 2023. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth quarter of 2026. "We made excellent progress this quarter advancing our I&I pipeline, including the ongoing Phase 2b studies of rezpegaldesleukin in atopic
– NKTR-255 administered post completion of concurrent chemoradiation and in combination with durvalumab demonstrated statistically significant lymphocyte recovery compared to historical controls at week 8 – – Pharmacodynamic data show NKTR-255 increased NK cell proliferation and markers of NK cell activation – SAN FRANCISCO, Nov. 7, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) and collaborators at The University of Texas MD Anderson Cancer Center today presented late-breaking results from a Phase 2 study evaluating NKTR-255 for the treatment of radiation induced lymphopenia after concurrent chemoradiation in locally advanced non-small cell lung cancer (NSCLC) patients at the Socie
Piper Sandler initiated coverage of Nektar Therapeutics with a rating of Overweight and set a new price target of $7.00
BTIG Research resumed coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $4.00
Rodman & Renshaw initiated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $2.00
Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh
BigHat Biosciences, a biotechnology company designing safer, more effective next-generation antibody therapies for patients using machine learning and synthetic biology, today announced that Rob Chess has been elected to BigHat's board of directors. Rob brings valuable experience in corporate biotech leadership and business strategy, from having led innovative and diverse teams from inception to successful exits to serving on the boards of multiple private and public life sciences companies. "We look forward to leveraging Rob's deep expertise in drug discovery and development to accelerate our work creating better antibody therapies for patients," said Mark DePristo, PhD., BigHat's CEO and
SAN FRANCISCO, Nov. 15, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced it has appointed Diana M. Brainard, M.D., as an independent director to its Board of Directors. Dr. Brainard brings over two decades of experience working in the healthcare sector and academia to Nektar. She currently serves as Chief Executive Officer (CEO) of AlloVir, Inc., a leading late clinical stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. "We are very ple